Health state utility and quality of life measures in patients with chronic myeloid leukemia in France von S, Foulon, P, Cony-Makhoul, A, Guerci-Bresler, M, Daban, R, Kapso, P, Tubert-Bitter, J, Bonastre

Volltext

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results von Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H

Volltext

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications von Damm, F, Thol, F, Kosmider, O, Kade, S, Löffeld, P, Dreyfus, F, Stamatoullas-Bastard, A, Tanguy-Schmidt, A, Beyne-Rauzy, O, de Botton, S, Guerci-Bresler, A, Göhring, G, Schlegelberger, B, Ganser, A, Bernard, O A, Fontenay, M, Heuser, M

Volltext

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS von Garelius, H., Smith, A., Bagguley, T., Taylor, A., Fenaux, P., Bowen, D., Symeonidis, A., Mittelmann, M., Stauder, R., Čermák, J., Sanz, G., Langemeijer, S., Malcovati, L., Germing, U., Itzykson, R., Guerci‐Bresler, A., Culligan, D., Kotsianidis, I., Koinig Mag, K., Marrewijk, C., Crouch, S., Witte, T., Hellström‐Lindberg, E.

Volltext

Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study von Huguet, F., Guerci‐Bresler, A., Roth‐Guepin, G., Cayssials, E., Slama, B., Santagostino, A., Penot, A., Quittet, P., Cony‐Makhoul, P., Saad, A., Bastie, J. N., Hacini, M., Coiteux, V., Uzunov, M., Roy, L., Le Clech, L., Berger, M., Agneray, A. M., Messas, E., Etienne, G., Turhan, A., Nicolini, F. E., Rousselot, P.

Volltext

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion von Toma, A, Kosmider, O, Chevret, S, Delaunay, J, Stamatoullas, A, Rose, C, Beyne-Rauzy, O, Banos, A, Guerci-Bresler, A, Wickenhauser, S, Caillot, D, Laribi, K, De Renzis, B, Bordessoule, D, Gardin, C, Slama, B, Sanhes, L, Gruson, B, Cony-Makhoul, P, Chouffi, B, Salanoubat, C, Benramdane, R, Legros, L, Wattel, E, Tertian, G, Bouabdallah, K, Guilhot, F, Taksin, A L, Cheze, S, Maloum, K, Nimuboma, S, Soussain, C, Isnard, F, Gyan, E, Petit, R, Lejeune, J, Sardnal, V, Renneville, A, Preudhomme, C, Fontenay, M, Fenaux, P, Dreyfus, F

Volltext

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias von Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

Volltext

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study von Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Abboud, Camille, Gjertsen, Bjørn Tore, Brümmendorf, Tim H., Smith, B. Douglas, Ernst, Thomas, Giraldo-Castellano, Pilar, Olsson-Strömberg, Ulla, Saussele, Susanne, Bardy-Bouxin, Nathalie, Viqueira, Andrea, Leip, Eric, Russell-Smith, T. Alexander, Leone, Jocelyn, Rosti, Gianantonio, Watts, Justin, Giles, Francis J.

Volltext

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukae... von Guilhot, Francois, Rigal-Huguet, Françoise, Guilhot, Joëlle, Guerci-Bresler, Agnès-Paule, Maloisel, Frédéric, Rea, Delphine, Coiteux, Valérie, Gardembas, Martine, Berthou, Christian, Vekhoff, Anne, Jourdan, Eric, Berger, Marc, Fouillard, Loïc, Alexis, Magda, Legros, Laurence, Rousselot, Philippe, Delmer, Alain, Lenain, Pascal, Escoffre Barbe, Martine, Gyan, Emmanuel, Bulabois, Claude-Eric, Dubruille, Viviane, Joly, Bertrand, Pollet, Bertrand, Cony-Makhoul, Pascale, Johnson-Ansah, Hyacinthe, Mercier, Melanie, Caillot, Denis, Charbonnier, Aude, Kiladjian, Jean-Jacques, Chapiro, Jacques, Penot, Amélie, Dorvaux, Véronique, Vaida, Iona, Santagostino, Alberto, Roy, Lydia, Zerazhi, Hacene, Deconinck, Eric, Maisonneuve, Herve, Plantier, Isabelle, Lebon, Delphine, Arkam, Yazid, Cambier, Nathalie, Ghomari, Kamel, Miclea, Jean-Michel, Glaisner, Sylvie, Cayuela, Jean-Michel, Chomel, Jean-Claude, Muller, Marc, Lhermitte, Ludovic, Delord, Marc, Preudhomme, Claude, Etienne, Gabriel, Mahon, François-Xavier, Nicolini, Franck- Emmanuel

Volltext

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia von Saglio, Giuseppe, Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Lobo, Clarisse, Pasquini, Ricardo, Clark, Richard E, Hochhaus, Andreas, Hughes, Timothy P, Gallagher, Neil, Hoenekopp, Albert, Dong, Mei, Haque, Ariful, Larson, Richard A, Kantarjian, Hagop M

Volltext

PB1923 PONATINIB LONG‐TERM FOLLOW‐UP OF EFFICACY AND SAFETY IN CP‐CML PATIENTS IN REAL WORLD SETTINGS IN FRANCE: THE POST‐PACE STUDY von Nicolini, F.‐E., Rea, D., Coiteux, V., Guerci‐Bresler, A., Huguet, F., Legros, L., Rousselot, P., Etienne, G.

Volltext

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial von Lipton, Jeffrey H, Prof, Chuah, Charles, MD, Guerci-Bresler, Agnès, MD, Rosti, Gianantonio, Prof, Simpson, David, Prof, Assouline, Sarit, MD, Etienne, Gabriel, MD, Nicolini, Franck E, MD, le Coutre, Philipp, Prof, Clark, Richard E, Prof, Stenke, Leif, MD, Andorsky, David, MD, Oehler, Vivian, MD, Lustgarten, Stephanie, PhD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Baccarani, Michele, Prof, Cortes, Jorge E, Prof, Guilhot, François, Prof, Hochhaus, Andreas, Prof, Hughes, Timothy, Prof, Kantarjian, Hagop M, Prof, Shah, Neil P, Prof, Talpaz, Moshe, Prof, Deininger, Michael W, Prof

Volltext

87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM von Ades, L, Guerci-Bresler, A, Makhoul, P. Cony, Legros, L, Delaunay, J, Recher, C, Sebert, M, Lejeune, J, Chevret, S, Fenaux, P

Volltext

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study i... von Huguet, Françoise, Cayuela, Jean‐Michel, Cambier, Nathalie, Carpentier, Nathalie, Tindel, Malka, Violet, Isabelle, Zunic, Patricia, Lascaux, Axelle, Etienne, Gabriel

Volltext

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis von Kuendgen, A, Lauseker, M, List, A F, Fenaux, P, Giagounidis, A A, Brandenburg, N A, Backstrom, J, Glasmacher, A, Hasford, J, Germing, U

Volltext

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study von Stauder, Reinhard, Yu, Ge, Koinig, Karin A., Bagguley, Tim, Fenaux, Pierre, Symeonidis, Argiris, Sanz, Guillermo, Cermak, Jaroslav, Mittelman, Moshe, Hellström-Lindberg, Eva, Langemeijer, Saskia, Holm, Mette Skov, Mądry, Krzysztof, Malcovati, Luca, Tatic, Aurelia, Germing, Ulrich, Savic, Aleksandar, van Marrewijk, Corine, Guerci-Bresler, Agnès, Luño, Elisa, Droste, Jackie, Efficace, Fabio, Smith, Alex, Bowen, David, de Witte, Theo

Volltext

Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry von Mądry, Krzysztof, Lis, Karol, Fenaux, Pierre, Bowen, David, Symeonidis, Argiris, Mittelman, Moshe, Stauder, Reinhard, Čermák, Jaroslav, Sanz, Guillermo, Hellström‐Lindberg, Eva, Langemeijer, Saskia, Malcovati, Luca, Germing, Ulrich, Holm, Mette Skov, Guerci‐Bresler, Agnes, Culligan, Dominic, Sanhes, Laurence, Kotsianidis, Ioannis, Marrewijk, Corine, Crouch, Simon, Witte, Theo, Smith, Alex

Volltext

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q von Fenaux, Pierre, Giagounidis, Aristoteles, Selleslag, Dominik, Beyne-Rauzy, Odile, Mufti, Ghulam, Mittelman, Moshe, Muus, Petra, te Boekhorst, Peter, Sanz, Guillermo, del Cañizo, Consuelo, Guerci-Bresler, Agnes, Nilsson, Lars, Platzbecker, Uwe, Lübbert, Michael, Quesnel, Bruno, Cazzola, Mario, Ganser, Arnold, Bowen, David, Schlegelberger, Brigitte, Aul, Carlo, Knight, Robert, Francis, John, Fu, Tommy, Hellström-Lindberg, Eva

Volltext

81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES von Park, S, Hamel, J.F, Kelaidi, C, Campelo, M. Diez, Schemenau, J, Sapena, R, Goetze, K, Mueller-Thomas, K, Beyne-Rauzy, O, Stamatoullas, A, Guerci-Bresler, A, Cony-Makhoul, P, Courby, S, Cheze, S, Rose, C, Vey, N, Germing, U, Sanz, G, Fenaux, P, Dreyfus, F

Volltext

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes von de Swart, Louise, Crouch, Simon, Hoeks, Marlijn, Smith, Alex, Langemeijer, Saskia, Fenaux, Pierre, Symeonidis, Argiris, Cermak, Jaroslav, Hellstrom-Lindberg, Eva, Stauder, Reinhard, Sanz, Guillermo, Mittelman, Moshe, Holm, Mette Skov, Malcovati, Luca, Madry, Krzysztof, Germing, Ulrich, Tatic, Aurelia, Savic, Aleksandar, Almeida, Antonio Medina, Gredelj-Simec, Njetocka, Guerci-Bresler, Agnes, Beyne-Rauzy, Odile, Culligan, Dominic, Kotsianidis, Ioannis, Itzykson, Raphael, van Marrewijk, Corine, Blijlevens, Nicole, Bowen, David, de Witte, Theo

Volltext